Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura

Kathryn Dane, Shruti Chaturvedi

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 539–547.

https://doi.org/10.1182/asheducation-2018.1.539

Published: 2018

Journal Articles

Fixed duration vs continuous therapy in multiple myeloma

Heinz Ludwig, Niklas Zojer

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 212–222.

https://doi.org/10.1182/asheducation-2017.1.212

Published: 2017

Journal Articles

Management of multiple myeloma in the relapsed/refractory patient

Pieter Sonneveld

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 508–517.

https://doi.org/10.1182/asheducation-2017.1.508

Published: 2017

Journal Articles

Myeloma: management of the newly diagnosed high-risk patient

Angela Dispenzieri

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 485–494.

https://doi.org/10.1182/asheducation-2016.1.485

Published: 2016

Journal Articles

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Andrew J. Yee, Noopur S. Raje

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 495–503.

https://doi.org/10.1182/asheducation-2016.1.495

Published: 2016

Journal Articles

Maintenance therapy for multiple myeloma in the era of novel agents

Thierry Facon

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 279–285.

https://doi.org/10.1182/asheducation-2015.1.279

Published: 2015

Journal Articles

Novel combination approaches for myeloma

Sagar Lonial, Ajay K. Nooka

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 286–293.

https://doi.org/10.1182/asheducation-2015.1.286

Published: 2015

Journal Articles

Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange

Paul Coppo, Antoine Froissart

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 637–643.

https://doi.org/10.1182/asheducation-2015.1.637

Published: 2015

Journal Articles

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Paul G. Richardson, Jacob P. Laubach, Nikhil C. Munshi, Kenneth C. Anderson

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 255–261.

https://doi.org/10.1182/asheducation-2014.1.255

Published: 2014

Journal Articles

Multiple myeloma: a model for scientific and clinical progress

Jesus San Miguel

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 1–7.

https://doi.org/10.1182/asheducation-2014.1.1

Published: 2014

Journal Articles

How should we treat newly diagnosed multiple myeloma patients?

María-Victoria Mateos, Jesús F. San Miguel

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 488–495.

https://doi.org/10.1182/asheducation-2013.1.488

Published: 2013

Journal Articles

Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients

Philip L. McCarthy, Theresa Hahn

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 496–503.

https://doi.org/10.1182/asheducation-2013.1.496

Published: 2013

Journal Articles

Have drug combinations supplanted stem cell transplantation in myeloma?

Antonio Palumbo, Federica Cavallo

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 335–341.

https://doi.org/10.1182/asheducation.V2012.1.335.3792205

Published: 2012

Journal Articles

Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?

S. Vincent Rajkumar

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 354–361.

https://doi.org/10.1182/asheducation.V2012.1.354.3798330

Published: 2012

Journal Articles

Many Multiple Myelomas: Making More of the Molecular Mayhem

Marta Chesi, P. Leif Bergsagel

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 344–353.

https://doi.org/10.1182/asheducation-2011.1.344

Published: 2011

Journal Articles

Posttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma

Donna E. Reece

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 197–204.

https://doi.org/10.1182/asheducation-2011.1.197

Published: 2011

Journal Articles

What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?

Emma Scott, Donna Reece

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 205–207.

https://doi.org/10.1182/asheducation-2011.1.205

Published: 2011

Journal Articles

Stem Cell Transplantation for Multiple Myeloma: Current and Future Status

Sergio Giralt

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 191–196.

https://doi.org/10.1182/asheducation-2011.1.191

Published: 2011

Journal Articles

Ultra High-Risk Myeloma

Hervé Avet-Loiseau

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 489–493.

https://doi.org/10.1182/asheducation-2010.1.489

Published: 2010

Journal Articles

Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy

Adam D. Cohen, Raymond L. Comenzo

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 287–294.

https://doi.org/10.1182/asheducation-2010.1.287

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura

Fixed duration vs continuous therapy in multiple myeloma

Management of multiple myeloma in the relapsed/refractory patient

Myeloma: management of the newly diagnosed high-risk patient

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Maintenance therapy for multiple myeloma in the era of novel agents

Novel combination approaches for myeloma

Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Multiple myeloma: a model for scientific and clinical progress

How should we treat newly diagnosed multiple myeloma patients?

Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients

Have drug combinations supplanted stem cell transplantation in myeloma?

Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?

Many Multiple Myelomas: Making More of the Molecular Mayhem

Posttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma

What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?

Stem Cell Transplantation for Multiple Myeloma: Current and Future Status

Ultra High-Risk Myeloma

Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy

ASH Publications

American Society of Hematology